{"pmid":32432977,"title":"Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.","text":["Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.","The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection.","Emerg Microbes Infect","Zhang, Ya-Nan","Zhang, Qiu-Yan","Li, Xiao-Dan","Xiong, Jin","Xiao, Shu-Qi","Wang, Zhen","Zhang, Zhe-Rui","Deng, Cheng-Lin","Yang, Xing-Lou","Wei, Hong-Ping","Yuan, Zhi-Ming","Ye, Han-Qing","Zhang, Bo","32432977"],"abstract":["The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection."],"journal":"Emerg Microbes Infect","authors":["Zhang, Ya-Nan","Zhang, Qiu-Yan","Li, Xiao-Dan","Xiong, Jin","Xiao, Shu-Qi","Wang, Zhen","Zhang, Zhe-Rui","Deng, Cheng-Lin","Yang, Xing-Lou","Wei, Hong-Ping","Yuan, Zhi-Ming","Ye, Han-Qing","Zhang, Bo"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32432977","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/22221751.2020.1772676","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288220585987,"score":9.490897,"similar":[{"pmid":32251767,"pmcid":"PMC7127386","title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","text":["Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.","Antiviral Res","Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling","32251767"],"abstract":["An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits."],"journal":"Antiviral Res","authors":["Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251767","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104786","keywords":["abstract","covid-19","emetine","homoharringtonine","lopinavir","remdesivir","ritonavir"],"e_drugs":["remdesivir","Ribavirin","Lopinavir","Emetine","favipiravir","Homoharringtonine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490993115138,"score":296.11887},{"pmid":32205232,"pmcid":"PMC7102548","title":"Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).","text":["Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).","PURPOSE: Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017). The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response. METHODS: The antiviral activity of LH against SARS-CoV-2 was assessed in Vero E6 cells using CPE and plaque reduction assay. The effect of LH on virion morphology was visualized under transmission electron microscope. Pro-inflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. RESULTS: LH significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines (TNF-alpha, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Furthermore, LH treatment resulted in abnormal particle morphology of virion in cells. CONCLUSIONS: LH significantly inhibits the SARS-COV-2 replication, affects virus morphology and exerts anti-inflammatory activity in vitro. These findings indicate that LH protects against the virus attack, making its use a novel strategy for controlling the COVID-19 disease.","Pharmacol Res","Runfeng, Li","Yunlong, Hou","Jicheng, Huang","Weiqi, Pan","Qinhai, Ma","Yongxia, Shi","Chufang, Li","Jin, Zhao","Zhenhua, Jia","Haiming, Jiang","Kui, Zheng","Shuxiang, Huang","Jun, Dai","Xiaobo, Li","Xiaotao, Hou","Lin, Wang","Nanshan, Zhong","Zifeng, Yang","32205232"],"abstract":["PURPOSE: Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017). The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response. METHODS: The antiviral activity of LH against SARS-CoV-2 was assessed in Vero E6 cells using CPE and plaque reduction assay. The effect of LH on virion morphology was visualized under transmission electron microscope. Pro-inflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. RESULTS: LH significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines (TNF-alpha, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Furthermore, LH treatment resulted in abnormal particle morphology of virion in cells. CONCLUSIONS: LH significantly inhibits the SARS-COV-2 replication, affects virus morphology and exerts anti-inflammatory activity in vitro. These findings indicate that LH protects against the virus attack, making its use a novel strategy for controlling the COVID-19 disease."],"journal":"Pharmacol Res","authors":["Runfeng, Li","Yunlong, Hou","Jicheng, Huang","Weiqi, Pan","Qinhai, Ma","Yongxia, Shi","Chufang, Li","Jin, Zhao","Zhenhua, Jia","Haiming, Jiang","Kui, Zheng","Shuxiang, Huang","Jun, Dai","Xiaobo, Li","Xiaotao, Hou","Lin, Wang","Nanshan, Zhong","Zifeng, Yang"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205232","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.phrs.2020.104761","keywords":["anti-inflammatory","coronavirus","lianhuaqingwen","sars-cov-2"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138490180468736,"score":248.86661},{"pmid":32253226,"pmcid":"PMC7199910","title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.","text":["An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.","Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog beta-d-N(4)-hydroxycytidine (NHC; EIDD-1931) has broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c bat-CoVs, as well as increased potency against a CoV bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC prodrug (beta-d-N(4)-hydroxycytidine-5'-isopropyl ester), improved pulmonary function and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral, but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple CoVs and oral bioavailability highlights its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic CoVs.","Sci Transl Med","Sheahan, Timothy P","Sims, Amy C","Zhou, Shuntai","Graham, Rachel L","Pruijssers, Andrea J","Agostini, Maria L","Leist, Sarah R","Schafer, Alexandra","Dinnon, Kenneth H 3rd","Stevens, Laura J","Chappell, James D","Lu, Xiaotao","Hughes, Tia M","George, Amelia S","Hill, Collin S","Montgomery, Stephanie A","Brown, Ariane J","Bluemling, Gregory R","Natchus, Michael G","Saindane, Manohar","Kolykhalov, Alexander A","Painter, George","Harcourt, Jennifer","Tamin, Azaibi","Thornburg, Natalie J","Swanstrom, Ronald","Denison, Mark R","Baric, Ralph S","32253226"],"abstract":["Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog beta-d-N(4)-hydroxycytidine (NHC; EIDD-1931) has broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c bat-CoVs, as well as increased potency against a CoV bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of EIDD-2801, an orally bioavailable NHC prodrug (beta-d-N(4)-hydroxycytidine-5'-isopropyl ester), improved pulmonary function and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral, but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple CoVs and oral bioavailability highlights its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic CoVs."],"journal":"Sci Transl Med","authors":["Sheahan, Timothy P","Sims, Amy C","Zhou, Shuntai","Graham, Rachel L","Pruijssers, Andrea J","Agostini, Maria L","Leist, Sarah R","Schafer, Alexandra","Dinnon, Kenneth H 3rd","Stevens, Laura J","Chappell, James D","Lu, Xiaotao","Hughes, Tia M","George, Amelia S","Hill, Collin S","Montgomery, Stephanie A","Brown, Ariane J","Bluemling, Gregory R","Natchus, Michael G","Saindane, Manohar","Kolykhalov, Alexander A","Painter, George","Harcourt, Jennifer","Tamin, Azaibi","Thornburg, Natalie J","Swanstrom, Ronald","Denison, Mark R","Baric, Ralph S"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253226","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1126/scitranslmed.abb5883","locations":["vivo"],"e_drugs":["remdesivir","Nucleosides","Ribonucleosides","N(4)-hydroxycytidine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493130113025,"score":242.98459},{"pmid":32094225,"pmcid":"PMC7152756","title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","text":["The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.","J Biol Chem","Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias","32094225"],"abstract":["Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays."],"journal":"J Biol Chem","authors":["Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32094225","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1074/jbc.AC120.013056","keywords":["ebola virus (ebov)","middle east respiratory syndrome coronavirus (mers-cov)","rna chain termination","rna-dependent rna polymerase (rdrp)","sars-cov-2","antiviral drug","coronavirus","drug development","enzyme inhibitor","nucleoside/nucleotide analog","plus-stranded rna virus","positive-sense rna virus","remdesivir","viral polymerase","viral replicase"],"e_drugs":["remdesivir","triphosphoric acid","Adenosine Triphosphate"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490805420032,"score":234.64703},{"pmid":32284326,"title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.","text":["Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.","Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA).","J Biol Chem","Gordon, Calvin J","Tchesnokov, Egor P","Woolner, Emma","Perry, Jason K","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias","32284326"],"abstract":["Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus (EBOV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain-termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the non-structural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i+3. We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps. A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP. In this regard, the triphosphate forms of 2'-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits. Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not observed. These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral (DAA)."],"journal":"J Biol Chem","authors":["Gordon, Calvin J","Tchesnokov, Egor P","Woolner, Emma","Perry, Jason K","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32284326","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1074/jbc.RA120.013679","keywords":["rna polymerase","drug action","drug development","drug discovery","plus-stranded rna virus"],"e_drugs":["remdesivir","triphosphoric acid","Sofosbuvir","Ribavirin","Adenosine Triphosphate","favipiravir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491332853760,"score":231.59045}]}